论文部分内容阅读
探讨在5种不同分子分型的乳腺癌中中期因子在组织中的表达,并分析其临床意义。采用免疫组化法检测203例乳腺癌组织的中期因子表达量;采用CD105抗体标记微血管内皮细胞,计算微血管密度(MVD)。结果显示,中期因子与肿瘤的淋巴结转移、临床分期相关性密切。中期因子表达量高的样本具有较高的以CD105表征的微血管密度。与其他4种分子分型相比,中期因子和CD105在基底细胞样型的表达量最高,但是该差异不具有统计学意义。中期因子可以作为乳腺癌预后的标记物应用于临床诊断和治疗,与其他分子亚型的乳腺癌相比,基底细胞样型的乳腺癌可能并不具有独特的血管生成模式。
To explore the expression of midkine in tissues of five different molecular types of breast cancer, and analyze their clinical significance. The expression of midkine in 203 breast cancer tissues was detected by immunohistochemistry. Microvascular endothelial cells were labeled with CD105 antibody and microvessel density (MVD) was calculated. The results showed that midkine was closely related to the lymph node metastasis and clinical stage of the tumor. Samples with high midkine expression had higher microvessel density characterized by CD105. The expression of midkine and CD105 in the basal cell-like pattern was highest compared with the other four types of molecular typing, but the difference was not statistically significant. Midkine can be used as a marker for prognosis of breast cancer for clinical diagnosis and treatment. Compared with other molecular subtypes of breast cancer, basal cell-type breast cancer may not have a unique angiogenesis pattern.